Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Little Growth Seen In Vaccine R&D for Rest of Decade
Tufts Center for the Study of Drug Development, 7-11-06

A recent study by the Tufts Center for the Study of Drug Development found that vaccine development has remained stagnant over the past decade, and that future development is not expected to increase significantly.

"Despite widespread agreement that new vaccines are an important public health priority, development remains slow, expensive, and risky," said Tufts CSDD Director Kenneth I Kaitin.

Each year from 2000 through 2004, clinical studies were initiated for 14 products, compared with an average of 12 each year from 1990 to 1999, according to findings reported in the July/August Tufts CSDD Impact Report, released today.

Since 1990, the study noted, the number of companies initiating study of new vaccines and the number of pathogens targeted—38 companies and 35 targets—have remained essentially unchanged.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000